factors must be considered when choosing a vector for a gene therapy trial?
477169
3. What factors must be considered when choosing a vector for a gene therapy trial? You must take into consideration the size of the gene, the possible immune response, the effectiveness, and what cells your targeting.
1427189
['The confounding factor must be associated with both the risk factor of interest and the outcome.', 'The confounding factor must be distributed unequally among the groups being compared.']
840021
What is gene therapy? Gene therapy for hemophilia involves using a modified virus (which does not cause disease) to introduce a copy of the gene that encodes for the clotting factor that's missing in patients. Following treatment with the virus, patients should begin producing their own clotting factor normally.
828139
['Transfer of the selected gene into other species. ... ', 'Some people believe it is not ethical to interfere with nature in this way. ... ', "GM crops could be harmful, for example toxins from the crops have been detected in some people's blood.", 'GM crops could cause allergic reactions in people.']
1072493
['Transfer of the selected gene into other species. ... ', 'Some people believe it is not ethical to interfere with nature in this way. ... ', "Genetically engineered crops could be harmful, for example toxins from the crops have been detected in some people's blood.", 'Genetically engineered crops could cause allergic reactions in people.']
103196
['It must be stable.', 'It must be capable of being expressed when needed.', 'It must be capable of accurate replication.', 'It must be transmitted from parent to progeny without change.']
968703
Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.
709815
A type of experimental treatment in which foreign genetic material (DNA or RNA) is inserted into a person's cells to prevent or fight disease. Gene therapy is being studied in the treatment of certain types of cancer.
316818
It must be stable. It must be capable of being expressed when needed. It must be capable of accurate replication. It must be transmitted from parent to progeny without change.
128262
The distinction between the two is based on purpose. Gene therapy seeks to alter genes to correct genetic defects and thus prevent or cure genetic diseases. Genetic engineering aims to modify the genes to enhance the capabilities of the organism beyond what is normal.
634699
Gene therapy replaces a faulty gene or adds a new gene in an attempt to cure disease or improve your body's ability to fight disease. Gene therapy holds promise for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.
938735
What are the hallmarks of successful gene delivery in gene therapy trials? Targeting the right cells, activating the gene, integrating the gene into the cells, avoiding harmful side effects.
903802
RESULTS. Among all participants combined, Auvi-Q was preferred over EpiPen an all study end points (P < . 001). For experienced and inexperienced participants in all 3 groups, Auvi-Q was preferred over EpiPen for method of instruction, preference to carry, and device size (all P < .
1142844
In recombinant DNA technology, plasmids are often used as vectors, DNA molecules that carry DNA fragments from one organism to another. ... The antibiotic kills all host cells that do not harbor the desired plasmid vector, but those that contain the vector are able to survive and grow.
923202
Gene therapy for hemophilia involves using a modified virus (which does not cause disease) to introduce a copy of the gene that encodes for the clotting factor that's missing in patients. Following treatment with the virus, patients should begin producing their own clotting factor normally.
649282
Gene therapy involves the transfer of correct copies of cystic fibrosis transmembrane conductance regulator (CFTR) DNA to the epithelial cells in the airways. The cloning of the CFTR gene in 1989 led to proof-of-principle studies of CFTR gene transfer in vitro and in animal models.
86677
Identifying Potential Risks (PI Input) Investigators should be aware that risks would include immediate risks of study participation, risks of randomization (especially to placebo groups in medical and pharmaceutical research), risks of breach of confidentiality, and risks of long term effects.